Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Says Acquisitions Could Help It Bolster Cell Reagent Play

GENEVA, Sept. 16 (GenomeWeb News) - PerkinElmer is "highly interested" in investing in its cell-based assay and reagent businesses, and will likely attempt to obtain core competencies in these areas through acquisition, partnerships, or both in the coming year, a PerkinElmer official said at the Society for Biomolecular Screening conference here this week.

 

Deb Brusini, business unit leader for drug discovery within PerkinElmer's Life and Analytical Sciences division, said in an interview with GenomeWeb News sister publication Cell-Based Assay News that the company will be looking to add reagents such as advanced photoproteins to better enable its newly launched LumiLux high-throughput live-cell ion-channel screening instrument.

 

The company will also aim to obtain optimized cell lines with the hope of enabling "mix-and-measure"-type assays on its CellLux and LumiLux instruments and, further in the future, acquire optimized reagents for conducting FRAP and FRET analysis on its UltraView confocal reader.

 

Brusini said that although PerkinElmer already has internal programs in place to address the development of these technologies, "it's very hard to get that internal capability on your own. So in the future what we'll be doing a lot of is acquiring competency in this area, as well as looking for technology to acquire in this area.

 

"The things that we'll be interested in will be anything that will allow these live-cell assays to be done more effectively," Brusini said.

 

Examples of possibly attainable companies with core competencies and key technologies in this area include Danish biotech BioImage and Italian biotech Axxam, though Brusini stressed that PerkinElmer is not necessarily interested in acquiring those particular companies. Brusini also said that Invitrogen would be an example of a company that would be attractive for a partnership in this area.

 

An extended version of this article appears in the current issue of Cell-Based Assay News.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.